结核与肺部疾病杂志 ›› 2023, Vol. 4 ›› Issue (3): 198-202.doi: 10.19983/j.issn.2096-8493.20230037
收稿日期:
2023-03-05
出版日期:
2023-06-20
发布日期:
2023-06-16
通信作者:
宋言峥,Email:基金资助:
Li Leilei1, Gao Jingtao2, Wang Lin1, Song Yanzheng1()
Received:
2023-03-05
Online:
2023-06-20
Published:
2023-06-16
Contact:
Song Yanzheng, Email: Supported by:
摘要:
美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)是32家权威癌症中心组成的学术机构,每年定期发布多种恶性肿瘤的临床诊治指南,其肿瘤诊治指南目前在国内外广泛应用。2023年第1版《HIV感染者恶性肿瘤临床实践指南》公布了艾滋病相关恶性肿瘤和非艾滋病相关恶性肿瘤的诊治指南,相比2021年版NCCN指南,在HIV感染者肺癌的筛查、诊断、免疫治疗等方面进行了更新。本文作者对2023年NCCN《HIV感染者恶性肿瘤临床实践指南》中的非小细胞肺癌部分进行了解读和讨论,为临床医生的医疗实践工作提供参考依据。
中图分类号:
李蕾蕾, 高静韬, 王琳, 宋言峥. 美国国家综合癌症网络《HIV感染者恶性肿瘤临床实践指南》(2023年第1版)非小细胞肺癌部分解读[J]. 结核与肺部疾病杂志, 2023, 4(3): 198-202. doi: 10.19983/j.issn.2096-8493.20230037
Li Leilei, Gao Jingtao, Wang Lin, Song Yanzheng. Interpretation of the National Comprehensive Cancer Network Clinical Practice Guidelines for Malignant Tumors in HIV-infected Patients (version 1, 2023) in non-small cell lung cancer[J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 198-202. doi: 10.19983/j.issn.2096-8493.20230037
[1] | Reid E, Suneja G, Al-Rohil R, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Cancer in People with HIV (Version 1. 2023)[EB/OL]. (2022-12-20) [2023-05-04]. https://www.nccn.org/professionals/physician_gls/pdf/hiv.pdf. |
[2] |
Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer, 2008, 123(1): 187-194. doi:10.1002/ijc.23487.
doi: 10.1002/ijc.23487 pmid: 18435450 |
[3] |
Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst, 2015, 107(4): dju503. doi:10.1093/jnci/dju503.
doi: 10.1093/jnci/dju503 |
[4] |
National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409. doi:10.1056/NEJMoa1102873.
doi: 10.1056/NEJMoa1102873 URL |
[5] |
National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med, 2013, 368(21): 1980-1991. doi:10.1056/NEJMoa1209120.
doi: 10.1056/NEJMoa1209120 URL |
[6] |
Davison JM, Subramaniam RM, Surasi DS, et al. FDG PET/CT in patients with HIV. AJR Am J Roentgenol, 2011, 197(2): 284-294. doi:10.2214/AJR.10.6332.
doi: 10.2214/AJR.10.6332 URL |
[7] | Goodman PC. Radiographic Assessment of HIV-Associated Diseases. HIV InSite 2006[EB/OL]. [2023-05-04]. https://hivinsite.ucsf.edu/InSite?page=kb-04-01-16#S1X. |
[8] |
Allen CM, Al-Jahdali HH, Irion KL, et al. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med, 2010, 5(4): 201-216. doi:10.4103/1817-1737.69106.
doi: 10.4103/1817-1737.69106 pmid: 20981180 |
[9] |
Strategies for Management of Antiretroviral Therapy SMART Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 2006, 355(22): 2283-2296. doi:10.1056/NEJMoa062360.
doi: 10.1056/NEJMoa062360 URL |
[10] |
Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol, 2007, 165(10): 1143-1153. doi:10.1093/aje/kwm017.
doi: 10.1093/aje/kwm017 pmid: 17344204 |
[11] |
Gérard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr, 2002, 30(5): 478-484. doi:10.1097/00126334-200208150-00003.
doi: 10.1097/00126334-200208150-00003 URL |
[12] | Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents[EB/OL]. [2023-05-04]. https://aidsetc.org/resource/guidelines-use-antiretroviral-agents-hiv-1-infected-adults-and-adolescents. |
[13] |
Calkins KL, Chander G, Joshu CE, et al. Immune Status and Associated Mortality After Cancer Treatment Among Indivi-duals With HIV in the Antiretroviral Therapy Era. JAMA Oncol, 2020, 6(2): 227-235. doi:10.1001/jamaoncol.2019.4648.
doi: 10.1001/jamaoncol.2019.4648 pmid: 31804663 |
[14] |
Sparano JA, Hu X, Wiernik PH, et al. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma treated with chemotherapy. J Natl Cancer Inst, 1997, 89(4): 301-307. doi:10.1093/jnci/89.4.301.
doi: 10.1093/jnci/89.4.301 pmid: 9048834 |
[15] |
Ngidi S, Magula N, Sartorius B, et al. Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy. S Afr Med J, 2017, 107(7): 595-601. doi:10.7196/SAMJ.2017.v107i7.12309.
doi: 10.7196/SAMJ.2017.v107i7.12309 URL |
[16] |
Park J, Kim TM, Hwang JH, et al. Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma. J Korean Med Sci, 2012, 27(12): 1468-1471. doi:10.3346/jkms.2012.27.12.1468.
doi: 10.3346/jkms.2012.27.12.1468 pmid: 23255844 |
[17] |
Alfa-Wali M, Dalla Pria A, Nelson M, et al. Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol, 2016, 42(6): 813-816. doi:10.1016/j.ejso.2016.02.253.
doi: 10.1016/j.ejso.2016.02.253 pmid: 27012999 |
[18] |
Leeds IL, Alturki H, Canner JK, et al. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol, 2016, 14(1): 208. doi:10.1186/s12957-016-0970-x.
doi: 10.1186/s12957-016-0970-x pmid: 27495294 |
[19] |
Lefèvre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol, 2012, 19(13): 4186-4192. doi:10.1245/s10434-012-2485-1.
doi: 10.1245/s10434-012-2485-1 pmid: 22825769 |
[20] |
Izadmehr S, Leapman M, Hobbs AR, et al. Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer. Int Urol Nephrol, 2016, 48(10):1639-1645. doi:10.1007/s11255-016-1338-4.
doi: 10.1007/s11255-016-1338-4 pmid: 27318820 |
[21] |
Silberstein JL, Parsons JK, Palazzi-Churas K, et al. Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer Prostatic Dis, 2010, 13(4): 328-332. doi:10.1038/pcan.2010.35.
doi: 10.1038/pcan.2010.35 |
[22] |
Sigel C, Cavalcanti MS, Daniel T, et al. Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiol Biomarkers Prev, 2016, 25(7): 1098-1104. doi:10.1158/1055-9965.EPI-15-1179.
doi: 10.1158/1055-9965.EPI-15-1179 URL |
[23] |
Wang L, Chen Y, Wang Y, et al. Lung cancer surgery in HIV-infected patients: An analysis of postoperative complications and long-term survival. Thorac Cancer, 2020, 11(8): 2146-2154. doi:10.1111/1759-7714.13519.
doi: 10.1111/1759-7714.13519 URL |
[24] |
Wang L, Wu L, Liu J, et al. Prognostic nomogram for surgery of lung cancer in HIV-infected patients. J Thorac Dis, 2021, 13(1):76-81. doi:10.21037/jtd-20-2268.
doi: 10.21037/jtd-20-2268 pmid: 33569187 |
[25] |
Sparano JA, Wiernik PH, Hu X, et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma. Med Oncol, 1998, 15(1):50-57. doi:10.1007/BF02787345.
doi: 10.1007/BF02787345 pmid: 9643531 |
[26] |
Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol, 2011, 12(9): 905-912. doi:10.1016/S1470-2045(11)70056-0.
doi: 10.1016/S1470-2045(11)70056-0 pmid: 21570912 |
[27] |
Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis, 2014, 59(1): 106-114. doi:10.1093/cid/ciu174.
doi: 10.1093/cid/ciu174 pmid: 24642555 |
[28] |
Larson KB, Wang K, Delille C, et al. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet, 2014, 53(10): 865-872. doi:10.1007/s40262-014-0167-9.
doi: 10.1007/s40262-014-0167-9 pmid: 25164142 |
[29] |
Deeken JF, Beumer JH, Anders NM, et al. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemother Pharmacol, 2015, 76(4): 813-819. doi:10.1007/s00280-015-2856-y.
doi: 10.1007/s00280-015-2856-y URL |
[30] |
Casado JL, Machuca I, Bañón S, et al. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy. Antivir Ther, 2015, 20(7): 773-777. doi:10.3851/IMP2961.
doi: 10.3851/IMP2961 pmid: 25879675 |
[31] |
Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect, 2014, 20(10): O672-679. doi:10.1111/1469-0691.12589.
doi: 10.1111/1469-0691.12589 URL |
[32] |
Shah NJ, Al-Shbool G, Blackburn M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer, 2019, 7(1): 353. doi:10.1186/s40425-019-0771-1.
doi: 10.1186/s40425-019-0771-1 pmid: 31847881 |
[33] |
Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD 4 count on the outcome and treatment tole-rance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys, 1999, 44(1): 127-131. doi:10.1016/s0360-3016(98)00528-8.
doi: 10.1016/s0360-3016(98)00528-8 URL |
[34] |
Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology, 1994, 193(1): 251-254. doi:10.1148/radiology.193.1.8090901.
doi: 10.1148/radiology.193.1.8090901 pmid: 8090901 |
[35] |
Kim JH, Sarani B, Orkin BA, et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum, 2001, 44(10): 1496-1502. doi:10.1007/BF02234605.
doi: 10.1007/BF02234605 pmid: 11598480 |
[36] |
Alongi F, Giaj-Levra N, Sciascia S, et al. Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncol, 2017, 18(7): e379-e393. doi:10.1016/S1470-2045(17)30440-0.
doi: 10.1016/S1470-2045(17)30440-0 URL |
[1] | 范明宽, 张慧. 《中国社区肺结核主动筛查循证指南》解读[J]. 结核与肺部疾病杂志, 2023, 4(1): 1-4. |
[2] | 罗丹, 陈松华, 张钰, 王伟, 吴倩, 吴勇浩, 刘魁, 陈彬. 2015—2021年浙江省MTB/HIV双重感染筛查现况及趋势分析[J]. 结核与肺部疾病杂志, 2022, 3(6): 443-448. |
[3] | 杨蕊, 许琳, 李玲. 2010—2020年云南省MTB/HIV双重感染流行特征分析[J]. 结核与肺部疾病杂志, 2022, 3(6): 437-442. |
[4] | 刘盛盛, 唐神结. 《非结核分枝杆菌病诊断与治疗指南(2020年版)》解读[J]. 结核与肺部疾病杂志, 2021, 2(2): 108-115. |
[5] | 王艳, 何畏, 黄涛, 吴桂辉. HIV感染/AIDS并发结核病住院患者发生药物性肝损伤的影响因素分析[J]. 结核与肺部疾病杂志, 2020, 1(1): 65-70. |
[6] | 傅小燕, 黄涛, 陈晴, 何畏, 黄晓秋, 吴桂辉. 263例结核病并发HIV感染成年患者MTB耐药及耐药基因突变检测结果分析[J]. 结核与肺部疾病杂志, 2020, 1(1): 55-59. |
[7] | 吴桂辉, 黄涛. TB/HIV双重感染者治疗中的问题与建议[J]. 结核与肺部疾病杂志, 2020, 1(1): 11-16. |
[8] | 余艳艳,谭云洪,陈振华,陈忠南,刘彬彬,王珏. 酶联免疫吸附试验在诊断HIV感染并发结核病患者中的价值[J]. 结核病与肺部健康杂志, 2018, 7(4): 288-292. |
[9] | 唐怡敏,叶涛生,邓国防,等. 艾滋病并发菌阴肺结核诊治中支气管肺泡灌洗液检测的应用进展[J]. 结核病与肺部健康杂志, 2017, 6(1): 68-72. |
[10] | 薛声波,吴桂辉,何畏,等. 艾滋病并发肺结核患者行抗结核药物治疗的效果观察[J]. 结核病与肺部健康杂志, 2017, 6(1): 32-35. |
[11] | 邓国防,周泱. 浅谈HIV感染并发结核病患者的诊治问题[J]. 结核病与肺部健康杂志, 2017, 6(1): 16-20. |
[12] | 吴桂辉,刘勇. 艾滋病并发结核病诊治中需要关注的问题[J]. 结核病与肺部健康杂志, 2017, 6(1): 11-15. |
[13] | 张国华,张馨月,高大蕊,邹萍. 文山壮族苗族自治州HIV与Mtb双重感染疫情分析[J]. 结核病与肺部健康杂志, 2015, 4(2): 106-108. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||